Salivary duct carcinoma: Targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus

Journal of Clinical Oncology

Volumn 29, Issue 26, 2011, Pages

  Piha Paul, Sarina A ^a   Cohen, Philip R ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DOCETAXEL; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; TEMSIROLIMUS;

AGED; ARTICLE; ASPIRATION BIOPSY; CANCER INFILTRATION; CASE REPORT; CERVICAL LYMPHADENOPATHY; CHEMORADIOTHERAPY; CODON; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DNA SEQUENCE; GENE MUTATION; HEART INFARCTION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LYMPH VESSEL; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NERVE CELL; OBESITY; PERINEURIUM; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; SALIVARY GLAND CARCINOMA; SOLID TUMOR; STEREOTACTIC RADIOSURGERY;

AGED; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; SIROLIMUS; SKIN NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 80053047138     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.2095     Document Type: Article

References (31)

1. Ellis GL, Auclair PL: Tumors of the Salivary Glands. Washington, DC, Armed Forces Institute of Pathology, 1996
2. Kleinsasser O, Klein HJ, Hübner G: Salivary duct carcinoma: A group of salivary gland tumors analogous to mammary duct carcinoma [in German]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 192:100-105, 1968
3. Lewis JE, McKinney BC, Weiland LH, et al: Salivary duct carcinoma: Clinicopathologic and immunohistochemical review of 26 cases. Cancer 77:223-230, 1996 (Pubitemid 26023338)
4. McHugh JB, Visscher DW, Barnes EL: Update on selected salivary gland neoplasms. Arch Pathol Lab Med 133:1763-1774, 2009
5. Barnes L, Rao U, Krause J, et al: Salivary duct carcinoma: Part I - A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 78:64-73, 1994
6. Simpson RH, Clarke TJ, Sarsfield PT, et al: Salivary duct adenocarcinoma. Histopathology 18:229-235, 1991
7. Aygit AC, Top H, Cakir B, et al: Salivary duct carcinoma of the parotid gland metastasizing to the skin: A case report and review of the literature. Am J Dermatopathol 27:48-50, 2005 (Pubitemid 40189026)
8. Giltman L, Alderete M, Minkowitz S: Malignant mixed tumor of the parotid gland presenting as a scalp nodule: A case report. Hum Pathol 8:706-709, 1977 (Pubitemid 8235760)
9. Schwartz RA, Rubenstein DJ, Raventos A, et al: Inflammatory metastatic carcinoma of the parotid. Arch Dermatol 120:796-797, 1984
10. Tok J, Kao GF, Berberian BJ, et al: Cutaneous metastasis from a parotid adenocarcinoma: Report of a case with immunohistochemical findings and review of the literature. Am J Dermatopathol 17:303-306, 1995
11. Zanca A, Ferracini U, Bertazzoni MG: Telangiectatic metastasis from ductal carcinoma of the parotid gland. J Am Acad Dermatol 28:113-114, 1993 (Pubitemid 23019581)
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
13. Airoldi M, Pedani F, Succo G, et al: Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91:541-547, 2001 (Pubitemid 32105699)
14. Gilbert J, Li Y, Pinto HA, et al: Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group. Head Neck 28:197-204, 2006 (Pubitemid 43269885)
15. Airoldi M, Pedani F, Brando V, et al: Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori 75:252-256, 1989 (Pubitemid 19192950)
16. Alberts DS, Manning MR, Coulthard SW, et al: Adriamycin/cis-platinum/ cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 47:645-648, 1981
17. Belani CP, Eisenberger MA, Gray WC: Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol 16:197-202, 1988
18. Creagan ET, Woods JE, Rubin J, et al: Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 62:2313-2319, 1988
19. Dimery IW, Legha SS, Shirinian M, et al: Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 8:1056-1062, 1990 (Pubitemid 20200194)
20. Dreyfuss AI, Clark JR, Fallon BG, et al: Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 60:2869-2872, 1987 (Pubitemid 18005856)
21. Kaplan MJ, Johns ME, Cantrell RW: Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 95:165-170, 1986 (Pubitemid 16025390)
22. Licitra L, Cavina R, Grandi C, et al: Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma: A phase II trial of 22 patients. Ann Oncol 7:640-642, 1996 (Pubitemid 26285647)
23. Posner MR, Ervin TJ, Weichselbaum RR, et al: Chemotherapy of advanced salivary gland neoplasms. Cancer 50:2261-2264, 1982 (Pubitemid 13244155)
24. Tsukuda M, Kokatsu T, Ito K, et al: Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck. J Cancer Res Clin Oncol 119:756-758, 1993 (Pubitemid 23290466)
25. Venook AP, Tseng A Jr, Meyers FJ, et al: Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: A pilot study of the Northern California Oncology Group. J Clin Oncol 5:951-955, 1987 (Pubitemid 17120002)
26. White JD, Junor EJ, McGarva J, et al: Adenocarcinoma of the salivary gland? A chemo-sensitive disease. Clin Oncol (R Coll Radiol) 16:159-160, 2004 (Pubitemid 38344442)
27. Wu X, Senechal K, Neshat MS, et al: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/ Akt pathway. Proc Natl Acad Sci U S A 95:15587-15591, 1998 (Pubitemid 29018743)
28. Davies MA, Stemke-Hale K, Tellez C, et al: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99:1265-1268, 2008
29. Sato T, Nakashima A, Guo L, et al: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 29:2746-2752, 2010
30. Urano J, Sato T, Matsuo T, et al: Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci U S A 104:3514-3519, 2007 (Pubitemid 46364190)
31. Lim JJ, Kang S, Lee MR, et al: Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med 32:552-561, 2003 (Pubitemid 37175008)